2017 News Releases

Keyword Search
 
2017 | 2016 | 2015
DateTitle 
March 27, 2017Opiant Pharmaceuticals, Inc. Announces Results of Positron Emission Tomography (PET) Study of Naloxone Nasal Spray
SANTA MONICA, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced the completion of a study evaluating two doses of a naloxone nasal spray on the occupation of brain opiate receptors using PET imaging.  The study was commissioned by the National Institute for Health and Welfare of Finland and was carried out by researchers at... 
Printer Friendly Version
March 20, 2017Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
Topline Data Expected in the First Half of 2018 SANTA MONICA, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that the Company has initiated a Phase 2 clinical trial evaluating its novel nasally-delivered opioid antagonist candidate, OPNT001, as a potential treatment for Bulimia Nervosa. “Bulimia Nervosa is a serious and potentially life-... 
Printer Friendly Version
March 16, 2017Opiant Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the fiscal second quarter ended January 31, 2017 and provided an update on recent developments and upcoming milestones.     “Since the beginning of our fiscal second quarter, we have made significant progress on a number of corporate and clinical initiatives d... 
Printer Friendly Version
March 09, 2017Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings for Two New NARCAN® Nasal Spray Patents
Listings Significantly Strengthen IP Estate and Enhance NARCAN Product Exclusivity SANTA MONICA, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that its most recently issued U.S. patents, numbers 9,480,644 and 9,561,177 covering methods of use for NARCAN® Nasal Spray (“NARCAN”), are now listed in the U.S. Food and Drug Administration (FDA) ... 
Printer Friendly Version
February 28, 2017Opiant Pharmaceuticals, Inc. Receives FDA Feedback Supporting Clinical Development of OPNT002 for the Treatment of Alcohol Use Disorder
Company Plans Additional Clinical Trials This Year; Topline Data Expected in 2018 SANTA MONICA, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that the Company has received supportive feedback from the U.S. Food and Drug Administration on a proposed development plan for OPNT002, an intranasally-dosed opioid antagonist, for the treatment of A... 
Printer Friendly Version
February 06, 2017Opiant Pharmaceuticals, Inc. Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer
SANTA MONICA, Calif., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced the appointment of Phil Skolnick, Ph.D., D.Sc. (hon.) as Chief Scientific Officer, effective immediately. In his new position, Dr. Skolnick will lead Opiant’s research and development activities.     “I am delighted to welcome Dr. Skolnick to th... 
Printer Friendly Version
January 31, 2017Opiant Pharmaceuticals, Inc. Announces Establishment of Audit, Compensation and Nominating and Corporate Governance Committees
Company to pursue up-listing to a major stock exchange in 2017 SANTA MONICA, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that the Company’s Board of Directors has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. Copies of the Committee charters... 
Printer Friendly Version
January 26, 2017Opiant Pharmaceuticals, Inc. Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI) Nasal Spray
2mg Formulation Indicated for Patients At-Risk for Severe Opioid Withdrawal SANTA MONICA, Calif., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that the U.S. Food and Drug Administration has approved the 2mg formulation of NARCAN® Nasal Spray for opioid-dependent patients expected to be at risk for severe opioid w... 
Printer Friendly Version
January 11, 2017Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals
- Plans to Initiate Phase 2 Study in Bulimia Nervosa - - Company to Pursue Uplisting to a Major Stock Exchange - SANTA MONICA, Calif., Jan. 11, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced the company’s 2017 corporate and clinical goals. These corporate and clinical goals include Phase 2 clinical trial initiation, ongoin... 
Printer Friendly Version
January 09, 2017Opiant Pharmaceuticals Featured in Recent Media Highlighting NARCAN® Nasal Spray and Heroin Vaccine Development
SANTA MONICA, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, was recently featured in several publications highlighting NARCAN® Nasal Spray and Opiant’s development of a treatment for heroin addiction. In MedCity News, an article titled “In 2016, the opioid epidemic hit home” notes Opiant’s development of NARCAN® Nasal S... 
Printer Friendly Version
Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet